跳至主要内容
临床试验/NCT06966050
NCT06966050招募中不适用

Multi-center MRD Registry for Inflammatory Breast Cancer

M.D. Anderson Cancer Center2 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2025年5月5日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
200
试验地点
2
主要终点
European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire

研究概览

简要总结

To collect data from participants with IBC who may have had MRD testing and may have surgery in the future.

详细描述

Primary Objectives

-To determine the incidence of protocol specified pre-surgery MRD-positivity in IBC (assessment between completion of planned systemic therapy and surgery).

Secondary Objectives

  • To establish the feasibility of multi-institutional MRD data collection using standard of care Signatera analysis in IBC participants.
  • To evaluate the association of pre-surgery MRD to pathologic response.
  • To evaluate participant reported QOL for worry about recurrence based in participants receiving MRD results
  • To establish protocol-optional baseline and longitudinal MRD data collection in IBC participants and report the frequency of MRD longitudinally
  • To determine the median lead time between the first MRD-positive result and clinical recurrence.
  • To determine whether adjuvant therapies decrease the amount of MRD in participants, and the association with relapse.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Female or males ≥18 years of age with the ability to understand and sign a written
  • Participants who have a clinical diagnosis of stage III or IV inflammatory breast cancer (IBC).
  • Participants who are planning to have or already completed a minimum of one blood draw for Signatera testing, for which the result and clinical data can be deposited into the study database.
  • Participants must be within eight months of diagnosis and have not undergone breast surgery for this diagnosis of breast cancer.
  • Participants must be English-speaking.

排除标准

  • 未提供

结局指标

主要结局

European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire

时间窗: Through study completion; an average of 1 year

European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) Score scale: (1-30 questions to assess the impact of participants quality of life)

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验